Primary Menu

In muscle stem cells age matters

CHICAGO (Reuters) – A new understanding of the genes that make muscle cells may change the way researchers think about stem cell transplants for muscular dystrophy and muscle injuries, U.S. researchers said on Wednesday.

In a surprise finding, they said genes important for forming muscle cells in embryos and newborns are not normally active in adult stem cells.
And researchers hoping to use muscle stem cells in stem-cell transplant therapies should not assume genes that control early muscle development serve the same purpose in repairing adult muscle, Christoph Lepper and colleagues at the Carnegie Institution in Baltimore reported in the journal Nature.

Earlier studies have shown that two genes — Pax3 and Pax7 — control cells that give rise muscle in embryos, and Pax7 also helps build muscle in newborn mice.
To get a better understanding of their function, Lepper and colleagues studied these genes at various stages of development in live mice.

“I thought that if they are so important in the embryo, they must be important for adult muscle stem cells,” Lepper said in a statement.
The team used genetic engineering to suppress both the Pax3 and Pax7 genes in adult muscle stem cells, and they found that adult stem cells were still able to function normally.

“I was totally surprised to find that the muscle stem cells are normal without them,” Lepper said
The researchers then looked at whether the same was true in injured muscles, when muscle stem cells go to work making new muscle tissue.

To study this, they injured mouse leg muscles between the knee and ankle, and found the muscle stem cells were able to make new muscle, even without the two key embryonic muscle stem cell genes.
The team said the embryonic muscle cell genes appear to only be active in mice within the first three weeks after birth. After that, they believe the genes go quiet and allow a different set of genes to take over.

Finding those genes will be important as scientists pursue new treatments for diseases like muscular dystrophy, a genetic, degenerative disease that affects voluntary muscles, they said.
And they said teams should look at other types of stem cells to see how age might affect their properties, and they should take age of stem cells into account in transplant-based treatments.

Stem cells are basic cells that can become almost any type of cell in the body. Human stem cells can come from an embryo or an adult human. They have many possible uses in science and medicine, yet controversy surrounds them.

New research has identified rogue cells -- namely brain and muscle cells -- lurking within kidney organoids. Such cells make up only 10 to 20 percent of an organoid's cells, but their presence indicates that the 'recipes' used to coax stem cells into becoming kidney cells inadvertently are churning out other cell types.

A new study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Clinical trial based on this observation may revolutionize care for older adults with acute myeloid leukemia.

Researchers have developed a way to grow human heart tissue that can serve as a model for the upper chambers of the heart, known as the atria. The tissue, derived from human induced pluripotent stem cells (hiPCSs), beats, expresses genes, and responds to drugs in a manner similar to a real human atrium. The model […]

Scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer's and Parkinson's diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries. Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete […]

Promising findings from preclinical animal studies show the potential of gene therapy for treating incurable neurological disorders. Scientists have successfully used gene therapy to slow the progression and improve symptoms of disorders such as amyotrophic lateral sclerosis and Parkinson's disease.

A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia type 7 (SCA7) and validates a new form of therapy with the potential to treat neurogenetic diseases effectively and with […]